ibogaine is set for closer federal scrutiny as the White House drafts an executive order that would signal the Trump administration’s willingness to expand U. S. research into the psychedelic drug. The move could come as soon as this week, with President Trump expected to sign the order in Eastern Time, while the substance remains illegal in the United States. The focus is on safety and effectiveness, especially for post-traumatic stress disorder and traumatic brain injuries.
What the order would do
The draft order would not reclassify ibogaine for medical use at this time, and the drug would remain a Schedule I substance. That means it would stay in the same federal category as heroin and ecstasy, which are treated as drugs with no currently accepted medical use and a high potential for abuse. Instead, the action is aimed at opening the door to federal funding for more research.
Officials want to determine whether ibogaine is a legitimate treatment or, in one official’s words, “snake oil. ” The administration’s interest is especially tied to PTSD and traumatic brain injuries, with veterans highlighted as a group that could benefit if future research supports the drug’s use. The research phase is still described as early, and internal discussions on how the federal government might facilitate further study were still being worked out this week.
Why ibogaine is drawing attention
ibogaine is a naturally occurring compound from a shrub native to Africa. It is used in some countries to treat depression, anxiety, addiction, post-traumatic stress disorder and brain trauma, and Americans have been traveling to unregulated clinics, often in Mexico or the Caribbean, to take it because it is illegal at home.
The administration’s planned move comes after years of uneven interest in the drug’s possible role in addiction treatment and mental health care. Texas has already made a major push to study ibogaine, with Gov. Greg Abbott signing a bill last year approving $50 million for research. That state-level action underscores how the subject has shifted from fringe interest toward formal scientific review.
What the evidence shows so far
The scientific record remains limited. Most of the evidence so far comes from small observational studies and open-label trials, and only one double-blind, placebo-controlled randomized clinical trial has been completed. More advanced trials are now getting underway, but researchers say far larger studies are still needed before ibogaine can be considered safe or effective for any condition.
The safety concern most often cited is the heart. Ibogaine can cause dangerous heart rhythm disturbances that can be fatal. A 2023 review of 24 studies involving 705 people found that while the drug appeared to reduce withdrawal symptoms and craving, its heart toxicity and risk of death were worrying. That review found at least 27 deaths after ibogaine use.
Immediate reaction and next steps
A small study of 30 veterans published last July by Stanford Medicine found that ibogaine, when paired with intravenous magnesium to protect the heart, safely reduced post-traumatic stress disorder, anxiety and depression in veterans. But the study had only 30 participants and no placebo group, leaving too little evidence to know whether magnesium reliably lowers the risk.
White House spokespeople did not immediately comment. For now, the expected executive order would mark a political green light for more research, not approval for medical use, and ibogaine would remain tightly restricted even as federal attention intensifies in the days ahead.
